Leukemia Posts Page 2 on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Blinatumomab vs chemotherapy in the treatment of relapsed or unresponsive acute lymphoblastic leukemia

Posted by on Jun 23, 2019 in Leukemia | 0 comments

In a nutshell This study compared the safety and effectiveness of blinatumomab (Blincyto) with chemotherapy in the treatment of acute lymphoblastic leukemia (ALL). Researchers found the survival was higher with blinatumomab than chemotherapy alone. Some background Patients with unresponsive or relapsed ALL treated with chemotherapy have...

Read More

Combining ibrutinib and venetoclax for first-time treatment of chronic lymphocytic leukemia

Posted by on Jun 23, 2019 in Leukemia | 0 comments

In a nutshell This study wanted to research if the combination therapy of ibrutinib (Imbruvica) and venetoclax (Venclexta) was effective in the treatment of chronic lymphocytic leukemia (CLL). Researchers found that this combination therapy was an effective treatment for high-risk and older patients with CLL. Some background Chronic...

Read More

Stopping TKI treatment in chronic myeloid leukemia

Posted by on Jun 23, 2019 in Leukemia | 0 comments

In a nutshell This study was an update on the guidelines of stopping tyrosine kinase inhibitor (TKI) therapy in the treatment of chronic myeloid leukemia (CML). New guidelines confirm the safety of stopping TKI therapy in patients with CML. Some background Chronic myeloid leukemia is often treated with TKI therapy. These are drugs which...

Read More

Outcomes of patients with chronic myeloid leukemia who stop ponatinib therapy

Posted by on Jun 23, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effect of stopping ponatinib (Iclusig) therapy in patients with chronic myeloid leukemia (CML). Researchers found that overall survival was high in these patients who stopped ponatinib. Some background Ponatinib is a drug that is used to treat chronic myeloid leukemia (CML). It has many side effects related...

Read More

Managing side effects of ibrutinib treatment

Posted by on Jun 23, 2019 in Leukemia | 0 comments

In a nutshell This study summarised the side effects of ibrutinib (Imbruvica) and how to manage them.  Some background Ibrutinib is an FDA approved drug used to treat lymphoma and leukemia. It works on the immune cells in the body which may lead to many side effects. These include diarrhea, upper respiratory infections, bleeding, tiredness,...

Read More

The negative impact of aspergillosis in acute leukemia

Posted by on Jun 22, 2019 in Leukemia | 0 comments

In a nutshell This study examined the impact of aspergillosis lung infection on the outcomes of patients with acute leukemia. Researchers found that this infection can reduce survival in these patients. Some background Acute leukemia is a cancer of the bone marrow. This leads to an abnormal immune system. Aspergillosis is a fungal infection that...

Read More

Graft-versus-host disease in pediatric patients with acute leukemia after alloSCT

Posted by on Jun 16, 2019 in Leukemia | 0 comments

In a nutshell This study investigated the occurrence of graft-versus-host disease (GVHD) in pediatric patients who underwent an allogeneic stem cell transplant (alloSCT). This study concluded that both umbilical cord blood cells and bone marrow cells led to similar rates of GVHD in children with acute leukemia. Some background Allogeneic stem cell...

Read More

Looking for patients with Ph+ or BCR-ABL+ acute lymphoblastic leukemia to test a treatment combination

Posted by on Jun 14, 2019 in Leukemia | 0 comments

In a nutshell This phase 2 trial is evaluating the effectiveness of ponatinib (Iclusig) plus chemotherapy for patients with acute lymphoblastic leukemia (ALL) that is positive for the Philadelphia chromosome (Ph+) or the BCR-ABL gene (BCR-ABL+). The main outcome to be measured will be the number of patients who respond to treatment. This study is...

Read More

Looking for older patients with acute myeloid leukemia to test a new treatment combination

Posted by on Jun 14, 2019 in Leukemia | 0 comments

In a nutshell This study is evaluating how well CPI-613 plus chemotherapy works in older patients with acute myeloid leukemia (AML) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This trial is taking place across the United...

Read More

Outcomes of stem cell transplant for patients with acute lymphoblastic leukemia after inotuzumab ozogamicin treatment

Posted by on Jun 5, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes of allogeneic stem cell transplant (allo-SCT) after treatment with inotuzumab ozogamicin (Besponsa) for patients with relapsed/unresponsive acute lymphoblastic leukemia (ALL). This study concluded that allo-SCT provided optimal long-term survival benefit for these patients. Some...

Read More